Benitec Biopharma Inc. (BNTC)
| Market Cap | 431.49M +31.4% |
| Revenue (ttm) | n/a |
| Net Income | -41.54M |
| EPS | -0.93 |
| Shares Out | 34.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 168,874 |
| Open | 12.54 |
| Previous Close | 12.56 |
| Day's Range | 12.21 - 12.67 |
| 52-Week Range | 9.85 - 16.76 |
| Beta | 0.26 |
| Analysts | Strong Buy |
| Price Target | 24.17 (+92.44%) |
| Earnings Date | Sep 21, 2026 |
About BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disea... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BNTC stock is "Strong Buy." The 12-month stock price target is $24.17, which is an increase of 92.44% from the latest price.
News
Wedbush bullish on Benitec Biopharma, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target The firm believes that BB-301, an AAV gene therapy that has allowed…
Benitec Biopharma initiated with an Outperform at Wedbush
Wedbush initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $16 price target
Guggenheim downgrades Benitec to Neutral, terminates coverage
Guggenheim downgraded Benitec Biopharma (BNTC) to Neutral from Buy without a price target while subsequently terminating coverage of the name. Benitec is engaging with the FDA mid-year to formalize th...
Benitec Biopharma downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Debjit Chattopadhyay downgraded Benitec Biopharma (BNTC) to Neutral from Buy with no price target
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 2...
Benitec Biopharma Earnings release: Q3 2026
Benitec Biopharma released its Q3 2026 earnings on May 14, 2026, summarizing the period's financial results.
Benitec Biopharma Quarterly report: Q3 2026
Benitec Biopharma has published its Q3 2026 quarterly earnings report on May 14, 2026.
Benitec Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $25 price target BB-301 represents “an exciting opportunity in the rare disease space,” particularly for treat...
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the ...
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genet...
Benitec Biopharma announces interim Phase 1b/2a study of BB-301
Benitec Biopharma (BNTC) announced “promising” interim clinical results from the BB-301 Phase 1b/2a first-in-human study evaluating low dose and high dose BB-301 treatment for Oculopharyngeal Muscular...
Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year
“We continue to be encouraged by the benign safety profile and the durability of efficacy demonstrated in our BB-301 clinical development program,” said Jerel Banks, M.D., Ph.D., Executive Chairman an...
Benitec Biopharma Earnings release: Q2 2026
Benitec Biopharma released its Q2 2026 earnings on February 12, 2026, summarizing the period's financial results.
Benitec Biopharma Quarterly report: Q2 2026
Benitec Biopharma has published its Q2 2026 quarterly earnings report on February 12, 2026.
Benitec Biopharma files to sell 1.48M shares of common stock for holders
The company will not receive any of the proceeds from the sale of the common stock by the selling stockholders.
Benitec Biopharma Registration statement: Registration Filing
Benitec Biopharma filed a registration statement on January 30, 2026, providing details about a securities offering with the SEC.
Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study
Benitec Biopharma (BNTC) announced that the first patient treated in Cohort 1 of the BB-301 Phase 1b/2a clinical study evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dyst...
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with dee...
Benitec Biopharma Slides: Corporate presentation
Benitec Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Benitec Biopharma (BNTC) to $32 from $35 and keeps a Buy rating on the shares. The firm cites the…
Benitec Biopharma reports Q1 EPS (22c), consensus (33c)
“We are fortunate to have achieved several important milestones this year. We previously announced positive interim clinical study results from the Phase 1b/2a trial of BB-301, with a 100% responder…
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use i...
Benitec Biopharma Earnings release: Q1 2026
Benitec Biopharma released its Q1 2026 earnings on November 14, 2025, summarizing the period's financial results.
Benitec Biopharma Quarterly report: Q1 2026
Benitec Biopharma has published its Q1 2026 quarterly earnings report on November 14, 2025.
Benitec Biopharma Proxy statement: Proxy Filing
Benitec Biopharma filed a proxy statement on November 12, 2025, providing details for shareholder voting and corporate governance matters.